LENZ Therapeutics, Inc.
LENZ- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001815776
No open-market purchases or sales by LENZ Therapeutics, Inc. insiders were filed in the last 90 days; 145 institutions reported holding it in 13F filings for Q2 2026, worth $197.3M in total; no superinvestor holds it.
Q3 2021 vs. Q2 2021
How the institutions holding LENZ Therapeutics, Inc. changed between Q2 2021 and Q3 2021.
All holders in Q3 2021All holders in Q2 2021
| Measure | Q2 2021 | Q3 2021 | Change |
|---|---|---|---|
| Holders | 51 | 60 | +9 |
| Shares | 32.2M | 36.0M | +3.78M (+11.7%) |
| Value | $981.4M | $587.4M | −$394.1M (−40.2%) |
New holders (29)
Institutions that held LENZ Therapeutics, Inc. at the end of Q3 2021 but not at the end of Q2 2021.
Sold out (20)
Institutions that held LENZ Therapeutics, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| SB Management Ltd | 993,402 | $30.5M |
| Adage Capital Partners GP, L.L.C. | 300,000 | $9.22M |
| Suvretta Capital Management, LLC | 125,000 | $3.84M |
| Blackstone Group Inc. | 75,000 | $2.31M |
| LMR Partners LLP | 70,000 | $2.15M |
| Monashee Investment Management LLC | 60,000 | $1.84M |
| Pinz Capital Management, LP | 52,543 | $1.61M |
| Asymmetry Capital Management, L.P. | 51,039 | $1.57M |
| Squarepoint Ops LLC | 40,000 | $1.23M |
| Marshall Wace North America L.P. | 36,646 | $1.13M |
| Alyeska Investment Group, L.P. | 30,000 | $922.0K |
| Davidson Kempner Capital Management LP | 25,000 | $768.0K |
| Voloridge Investment Management, LLC | 20,000 | $615.0K |
| Balyasny Asset Management LLC | 19,232 | $591.0K |
| Jane Street Group, LLC | 15,225 | $468.0K |
| Qube Research & Technologies Ltd | 14,700 | $452.0K |
| Maven Securities LTD | 12,500 | $389.0K |
| Tudor Investment Corp Et Al | 12,000 | $369.0K |
| Virtu Financial LLC | 7,709 | $237.0K |
| Point72 Hong Kong Ltd | 2,576 | $79.0K |